ECO Animal Health Group (LON:EAH) Receives “Buy” Rating from Shore Capital

Shore Capital reiterated their buy rating on shares of ECO Animal Health Group (LON:EAH) in a research report released on Wednesday morning, Marketbeat Ratings reports.

ECO Animal Health Group Price Performance

LON:EAH opened at GBX 118.95 ($1.49) on Wednesday. ECO Animal Health Group has a 52-week low of GBX 82.67 ($1.04) and a 52-week high of GBX 124 ($1.56). The company has a quick ratio of 2.14, a current ratio of 3.16 and a debt-to-equity ratio of 4.57. The business’s 50-day moving average price is GBX 94.24 and its 200 day moving average price is GBX 102.62. The firm has a market cap of £80.57 million, a P/E ratio of -6,000.00 and a beta of 0.07.

ECO Animal Health Group Company Profile

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.